TSU-68 is a novel kinase inhibitor developed for cell signaling and oncology research. It has significant antitumor activity against many types of tumors by inducing apoptosis in vascular and tumor cells, perturbing tumor vasculature and inhibiting angiogenesis. TSU-68 inhibits the tyrosine kinase phosphorylation of VEGF, PDGF and bFGF receptors to block angiogenesis. Studies show it inhibits tumor proliferation and metastasis in colon cancer models by blocking tumor angiogenesis, but does not affect ovarian cancer cell proliferation directly. TSU-68 binds to VEGF and PDGF receptors to inhibit their phosphorylation rather than acting directly on the growth factors.